NASDAQ:PGEN 15 August 2025

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

On 14 November 2025, Precigen, Inc. is back in the spotlight. The gene‑therapy specialist’s stock is trading roughly 25–30% higher intraday around $4.90–$5.00, after closing at $3.86 on 13 November, on surging volume of nearly 11 million shares.StockAnalysis+1

14 November 2025

Biotechnology·Earnings Reports·NASDAQ:PGEN·Stock Market

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Key Facts Sources

27 August 2025

Biotechnology·Innovation·NASDAQ:PGEN·NYSE:ABBV·NYSE:LLY·Pharmaceuticals

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Sources: Original news reports, press releases and scientific publications from Aug 14–15, 2025 fda.gov fiercebiotech.com fiercepharma.com paho.org fiercebiotech.com, as cited above. Each development is attributed to reputable sources including FDA announcements, company press statements, peer-reviewed journals, and expert commentary to ensure accuracy and context.

15 August 2025

Innovation·NASDAQ:NVO·NASDAQ:PGEN·NASDAQ:PRTL